Takeda

Takeda (NYSE: TAK) is a Japanese R&D-driven pharmaceutical company that discovers and delivers life-transforming treatments. It has been listed on the Tokyo and Osaka stock exchanges since 1949. In 2018, Takeda was listed on the New York Stock Exchange, being the only pharmaceutical company listed on both the TSE and NYSE. In January 2019 , the company completed the acquisition of Shire and achieved global R&D-driven biopharmaceutical leadership with an operational presence in ~80 countries and regions. Takeda claims to be the leader for several decades in treating rare hematology and innovation of plasma solutions and is one of the top three plasma organizations in the world, offering the complete life cycle from donor to patient. Takeda generated revenue of JPY 4,027.5 billion (~USD 28.3 billion) in FY2023 (ended March 31).

Takeda’s Gastrointestinal (GI) segment (~27% of total revenue in FY2023) focuses on providing innovative therapeutics for patients suffering from GI and other inflammatory diseases. Rare diseases (~18%) consists of treatments for rare diseases in hematology and hemostasis, immunology, and metabolic. The company’s Plasma-Derived Therapies (PDT) segment (~17%) offers sustainable plasma solutions to treat patients with diseases such as immunodeficiencies and neuroimmunology and other chronic diseases. Takeda’s Neuroscience (~16%) segment provides solutions to treat patients with neurologic diseases and also includes patient awareness and education services. The relatively small Oncology (~11%) segment comprises innovative solutions to treat cancer patients. Takeda also offers vaccines to treat common spreads and challenging infectious diseases such as dengue and COVID-19.

Takeda had three research sites and more than 25 manufacturing sites as of FY2023. The US is Takeda’s largest market, accounting for ~52% of total revenue (FY2023), followed by the Europe and Canada segment (~21%). Japan as a single market made up ~13% of FY2023 revenue. Takeda expects FY2024 revenue growth to be negative 4.7% (12.8% YoY in FY2023) due to the loss of sales from two key medicines: VYVANSE and AZILVA and lower coronavirus vaccine revenue. Takade plans to achieve net-zero greenhouse gas (GHG) emissions across all operations by 2040.